{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:10:39Z","timestamp":1784574639773,"version":"3.55.0"},"reference-count":38,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Prostate cancer (PCa) is men\u2019s second most predominant cancer worldwide. Because the prostate-specific antigen test is used in diagnostics, PCa is more often diagnosed in the early stages, making radical treatment of the disease possible. However, it is estimated that over a million men worldwide suffer from radical treatment-related complications. Thus, focal treatment has been proposed as a solution, which aims to destroy the predominant lesson that determines the progression of the disease. The main objective of our study is to compare the quality of life and efficacy of patients diagnosed with PCa before and after the treatment with focal high-dose-rate brachytherapy and to compare results with focal low-dose-rate brachytherapy and active surveillance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>150 patients diagnosed with low-risk or favourable intermediate-risk PCa who meet the inclusion criteria will be enrolled in the study. Patients are going to be randomly assigned to the study groups: focal high-dose-rate brachytherapy (group 1), focal low-dose-rate brachytherapy (group 2) and active surveillance (group 3). The study\u2019s primary outcomes are quality of life after the procedure and time without biochemical disease recurrence. The secondary outcomes are early and late genitourinary and gastrointestinal reactions after the focal high-dose and low-dose-rate brachytherapies and evaluation of the importance and significance of in vivo dosimetry used for high-dose-rate brachytherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>Bioethics committee approval was obtained before this study. The trial results will be published in peer-reviewed journals and at conferences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>Vilnius regional bioethics committee; approval ID 2022\/6-1438-911.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-070020","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T15:00:29Z","timestamp":1684335629000},"page":"e070020","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable intermediate-risk prostate cancer\u2014a protocol for a randomised controlled trial"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-4383","authenticated-orcid":false,"given":"Justinas","family":"Jonu\u0161as","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-2723","authenticated-orcid":false,"given":"Ausvydas","family":"Patasius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantas","family":"Trakymas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Venius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernestas","family":"Janulionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-543X","authenticated-orcid":false,"given":"Giedre","family":"Smailyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Kincius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"2023060101554712000_13.5.e070020.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2023060101554712000_13.5.e070020.2","doi-asserted-by":"crossref","first-page":"v128","DOI":"10.1093\/annonc\/mdg756","article-title":"EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century","volume":"14 Suppl 5","author":"Coleman","year":"2003","journal-title":"Ann Oncol"},{"key":"2023060101554712000_13.5.e070020.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70546-1"},{"key":"2023060101554712000_13.5.e070020.4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123826"},{"key":"2023060101554712000_13.5.e070020.5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp278"},{"key":"2023060101554712000_13.5.e070020.6","doi-asserted-by":"crossref","unstructured":"Resnick MJ , Penson DF . Long-Term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368. doi:10.1056\/NEJMc1302509","DOI":"10.1056\/NEJMoa1209978"},{"key":"2023060101554712000_13.5.e070020.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70162-0"},{"key":"2023060101554712000_13.5.e070020.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113162"},{"key":"2023060101554712000_13.5.e070020.9"},{"key":"2023060101554712000_13.5.e070020.10","unstructured":"Mohler JL , Armstrong AJ , Bahnson RR . NCCN clinical practice guidelines in oncology: prostate cancer. Version 1. 2013. Available: NCCN.org"},{"key":"2023060101554712000_13.5.e070020.11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.purol.2021.08.037","article-title":"Focal therapy for prostate cancer: making the punishment fit the crime","volume":"31","author":"Aoun","year":"2021","journal-title":"Prog Urol"},{"key":"2023060101554712000_13.5.e070020.12","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000515"},{"key":"2023060101554712000_13.5.e070020.13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2016.08.044","article-title":"New and established technology in focal ablation of the prostate: a systematic review","volume":"71","author":"Valerio","year":"2017","journal-title":"Eur Urol"},{"key":"2023060101554712000_13.5.e070020.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70121-3"},{"key":"2023060101554712000_13.5.e070020.15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"key":"2023060101554712000_13.5.e070020.16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.urolonc.2021.11.009","article-title":"Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy","volume":"40","author":"Matsuoka","year":"2022","journal-title":"Urol Oncol"},{"key":"2023060101554712000_13.5.e070020.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.072"},{"key":"2023060101554712000_13.5.e070020.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01758-8"},{"key":"2023060101554712000_13.5.e070020.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00097-2"},{"key":"2023060101554712000_13.5.e070020.20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky","year":"2017","journal-title":"Nat Rev Urol"},{"key":"2023060101554712000_13.5.e070020.21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"2023060101554712000_13.5.e070020.22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.radonc.2020.12.021","article-title":"Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial","volume":"156","author":"Corkum","year":"2021","journal-title":"Radiother Oncol"},{"key":"2023060101554712000_13.5.e070020.23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ijrobp.2019.03.032","article-title":"Mri-Guided ultrafocal HDR brachytherapy for localized prostate cancer: median 4-year results of a feasibility study","volume":"104","author":"Peters","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023060101554712000_13.5.e070020.24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.brachy.2017.10.001","article-title":"Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy","volume":"17","author":"Mendez","year":"2018","journal-title":"Brachytherapy"},{"key":"2023060101554712000_13.5.e070020.25","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1002\/mp.12459","article-title":"A generic tg-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate 192 IR brachytherapy","volume":"44","author":"Ma","year":"2017","journal-title":"Med Phys"},{"key":"2023060101554712000_13.5.e070020.26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2016.03.011","article-title":"Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in retroembrace, a multicenter cohort study","volume":"120","author":"Sturdza","year":"2016","journal-title":"Radiother Oncol"},{"key":"2023060101554712000_13.5.e070020.27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2017.12.025","article-title":"Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer","volume":"127","author":"\u00c5str\u00f6m","year":"2018","journal-title":"Radiother Oncol"},{"key":"2023060101554712000_13.5.e070020.28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phro.2020.09.002","article-title":"In vivo dosimetry in brachytherapy: requirements and future directions for research, development, and clinical practice","volume":"16","author":"Fonseca","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"2023060101554712000_13.5.e070020.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2008.06.010"},{"key":"2023060101554712000_13.5.e070020.30","doi-asserted-by":"crossref","unstructured":"Tanderup K , Beddar S , Andersen CE , et al . In vivo dosimetry in brachytherapy. Med Phys 2013;40. doi:10.1118\/1.4810943","DOI":"10.1118\/1.4810943"},{"key":"2023060101554712000_13.5.e070020.31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00066-019-01561-3","article-title":"Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results","volume":"196","author":"Prada","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"2023060101554712000_13.5.e070020.32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2023060101554712000_13.5.e070020.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.07.030"},{"key":"2023060101554712000_13.5.e070020.34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900472"},{"key":"2023060101554712000_13.5.e070020.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.10.071"},{"key":"2023060101554712000_13.5.e070020.36","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-C"},{"key":"2023060101554712000_13.5.e070020.37","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.21037\/tau-21-508","article-title":"Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution","volume":"10","author":"Anderson","year":"2021","journal-title":"Transl Androl Urol"},{"key":"2023060101554712000_13.5.e070020.38","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5114\/jcb.2020.101688","article-title":"Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer","volume":"12","author":"Kunogi","year":"2020","journal-title":"J Contemp Brachytherapy"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-070020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:07:43Z","timestamp":1685610463000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-070020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,17]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-070020"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-070020","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}